For people living with osteoarthritis, news about potential new treatments often comes with more questions than answers. In this episode of The Health Advocates, we slow things down to explain what it really means when a company submits a New Drug Application, or NDA, to the U.S. Food and Drug Administration.

Steven Newmark is joined by Erich Horsley and Dr. Yusuf Yazici from Biosplice Therapeutics to walk through this important regulatory milestone and why it matters for patients. Together, they break down what an NDA is, what happens during FDA review, and what patients should and should not expect while a therapy is under evaluation. The conversation also explores the current osteoarthritis treatment landscape, why progress in this disease has been so challenging, and what researchers mean when they talk about disease-modifying approaches.

Contact Our Host

Steven Newmark, Chief of Policy at GHLF: snewmark@ghlf.org

A podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF.

We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.org

Listen to all episodes of The Health Advocates on our website or on your favorite podcast channel.

For people living with osteoarthritis, news about potential new treatments often comes with more questions than answers. In this episode of The Health Advocates, we slow things down to explain what it really means when a company submits a New Drug Application, or NDA, to the U.S. Food and Drug Administration.
Steven Newmark is joined by Erich Horsley and Dr. Yusuf Yazici from Biosplice Therapeutics to walk through this important regulatory milestone and why it matters for patients. Together, they break down what an NDA is, what happens during FDA review, and what patients should and should not expect while a therapy is under evaluation. The conversation also explores the current osteoarthritis treatment landscape, why progress in this disease has been so challenging, and what researchers mean when they talk about disease-modifying approaches.
Contact Our Host Steven Newmark, Chief of Policy at GHLF:&nbsp;<a href="mailto:snewmark@ghlf.org">snewmark@ghlf.org</a> A podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF. We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to <a href="mailto:podcasts@ghlf.org">podcasts@ghlf.org</a> Listen to all episodes of The Health Advocates on our <a href="https://ghlf.org/the-health-advocates">website</a> or on your favorite podcast channel.

A podcast that breaks down major health news of the week to help you make sense of it all. Our goal is to help you understand what’s happening in the healthcare world to help you make informed decisions to live your best life.

A podcast that breaks down major health news of the week to help you make sense of it all. Our goal is to help you understand what&rsquo;s happening in the healthcare world to help you make informed decisions to live your best life.

The Health Advocates

A podcast that breaks down major health news of the week to help you make sense of it all. Our goal is to help you understand what’s happening in the healthcare world to help you make informed decisions to live your best life. The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Steven Newmark, Chief of Policy at GHLF, and Zoe Rothblatt, Director of Community Outreach at GHLF.

A podcast that breaks down major health news of the week to help you make sense of it all. Our goal is to help you understand what’s happening in the healthcare world to help you make informed decisions to live your best life. The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Steven Newmark, Chief of Policy at GHLF, and Zoe Rothblatt, Director of Community Outreach at GHLF.